Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Publish Ahead of Print published online ahead of print December 10, 2007
DOI: 10.2337/db07-0847

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-0847v1
57/3/645    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shu, L.
Right arrow Articles by Maedler, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shu, L.
Right arrow Articles by Maedler, K.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

TCF7L2 regulates β-cell survival and function in human pancreatic islets

Luan Shu1, Nadine S. Sauter1, Fabienne T. Schulthess1, Aleksey V. Matveyenko1, José Oberholzer2, and Kathrin Maedler1

1Larry L. Hillblom Islet Research Center, Department of Medicine, UCLA, Los Angeles, CA 90024-2852
2Division of Transplantation, University of Illinois at Chicago, Chicago, IL 60612, USA

Objective: Type 2 diabetes mellitus (T2DM) is characterized by impaired insulin secretion in response to increased metabolic demand. This defect in β-cell compensation seems to result from the interplay between environmental factors and genetic pre-disposition. Genome wide association studies reveal that common variants in the transcription factor TCF7L2 are associated with increased risk of T2DM. The aim of the present study was to establish if TCF7L2 plays a role in β-cell function and/or survival.

Research Design and Methods: To investigate the effects of TCFL7L2 depletion, isolated islets were exposed to TCF7L2 siRNA versus scrambled siRNA and β-cell survival and function were examined. For TCF7L2 over-expression islets were cultured in glucose concentrations of 5.5-33.3 mM and the cytokine mix IL-1β/IFN-{gamma} with or without over-expression of TCF7L2. Subsequently, glucose stimulated insulin secretion (GSIS), β-cell apoptosis (by TUNEL assay and Western blotting for PARP and Caspase-3 cleavage) and β-cell proliferation (by Ki67 immunostaining) were analyzed.

Results: Depleting TCF7L2 by siRNA resulted in a 5.1-fold increase in β-cell apoptosis, 2.2-fold decrease in β-cell proliferation (p<0.001) and 2.6-fold decrease in GSIS (p<0.01) in human islets. Similarly, loss of TCF7L2 resulted in impaired β-cell function in mouse islets. In contrast, over-expression of TCF7L2 protected islets from glucose and cytokine induced apoptosis and impaired function.

Conclusions: TCF7L2 is required for maintaining glucose stimulated insulin secretion and β-cell survival. Changes in the level of active TCF7L2 in β-cells from carriers of at risk allele may be the reason for defective insulin secretion and progression of type 2 diabetes.


Correspondence: kmaedler{at}mednet.ucla.edu

Key Words: TCF7L2 • islets • apoptosis • insulin secretion • T2DM


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.